How does RYTM's earnings trend compare to industry peers?

Rhythm Pharmaceuticals (RYTM) has a negative net income of $43.29 million, while its peers, Eli Lilly (LLY), Merck (MRK), and Pfizer (PFE), have significantly higher net incomes of $4.41 billion, $3.75 billion, and $418 million, respectively. This indicates that RYTM's earnings trend is significantly weaker than that of its industry peers.